RxDoctor Payments Data

Anne Copeland

Family · Weirton, WVNPI 1386995165

Payments from drug & device makers

$1,562in general payments, 2019–2025

Across 70 payments — averaging $22.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$355
  • Novo Nordisk$178
  • Esperion Therapeutics, Inc.$148
  • AbbVie$137
  • Xeris Pharmaceuticals, Inc.$135
  • AstraZeneca$128
  • plus $481 from 12 others

What the payments were for

  • Food & beverage$1,562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,562 in reported general payments places this provider in the 75th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$4,985
Medicare patients
47
Services billed
75

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl14$9,575
Fenofibrate53$8,227
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp15$5,463
Levothyroxine Sodium334$3,433
SynthroidLevothyroxine Sodium41$1,340
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$936
Potassium Chloride40$701
Lisinopril121$698
FenofibrateFenofibrate,micronized24$656
Buspirone Hcl30$622
Pantoprazole Sodium86$622
Atorvastatin Calcium131$501
Pravastatin Sodium59$436
Simvastatin66$433
ClopidogrelClopidogrel Bisulfate20$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet$55$9,57514 claims
AbbVieSynthroid$137$1,34041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,507 family providers in West Virginia.

Other family in Weirton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →